Newsletters
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
Let’s help Alan Carr do a COVID-19 point insight survey
Dear All, I promise that the next email will be all about the 25 Mar 2020 NHS England webinar on ...
Read More >
Send a note to your congressman/woman today!
Dear All, If you are a US citizen, you have an opportunity right now (as in today/tomorrow) to push for ...
Read More >
Tetraphase sold for $14m … and $600m goes up in smoke!
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter): Wonkish and long note alert … top-up your coffee ...
Read More >
Sweden to test an access-focused model for new antibiotics: Contracting for Availability
Dear All: Sweden has been a steady supporter of work on incentives for antibiotics for over a decade – as ...
Read More >
NHS England antibiotic procurement pilot project: Update webinar on 25 Mar 2020
Dear All, This email was just today received from the team leading the NHS England antibiotic procurement project (go here ...
Read More >
WHO R&D-focused consultancy: Data coordinator for next WHO pipeline review
Dear All, As you know, WHO has been driving a series of clinical and preclinical pipeline reviews (go here for ...
Read More >
FDA Workshop: Animal Models To Support Antibacterial Development (5 Mar 2020, post-meeting notes)
Dear All (detailed and wonkish note alert … lots of thinking out loud … get some coffee and settle in!), ...
Read More >
What does an antibiotic cost to develop? What is it worth? How to afford it?
Dear All (long, wonkish note alert!): Today we have a 3-part discussion of cost and value with this summary 3-part ...
Read More >
Glaxo seeks buyer for two of its older antibiotics / AMR podcasts to share
Heads-up … numerous changes in the meeting calendar: Lots of new events as well as rescheduling of previously announced events. ...
Read More >
Consultancy at WHO: manage a fund for implementation of AMR-focused actions / 17 Mar 2020 deadline
Dear All, A fascinating job posting has gone up from WHO and the full text is just below my signature. ...
Read More >
Chemicals vs. drugs (Part 3): XKCD has the final word
This newsletter is part of a series — here are the links to Part 1, Part 2, (this one is Part ...
Read More >
WHO consultancy to support AMR-related messaging / 2 Mar 2020 deadline!
Dear All, WHO has just posted a job opening for a consultant in Geneva to help with spreading the word ...
Read More >
Chemical vs. drugs (Part 2): How do you discriminate? / More on halicin
This newsletter is part of a series — here are the links to Part 1, (this one is Part 2), Part ...
Read More >
Chemicals vs. drugs (Part 1): The end of bacitracin / the buzz around halicin
This newsletter is the first of a series — here are the links to Part 2, Part 3, Part 4, and ...
Read More >
Language matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs. DTR
Note: See also these related newsletters: 13 Jan 2019 (link) on DTR as part of the language of resistance and ...
Read More >
Novel Biology, Novel Utility, & the Illusion of Skill: What to develop? What to reward?
Dear All (wonk-ish note alert and also with particular thanks as always to Kevin Outterson for helping to refine this ...
Read More >
FDA workshop: Animal models to support antibacterial development (5 Mar 2020)
Dear All (moderately long note alert; be sure to note the new list of funding opportunities just below my signature), ...
Read More >
Jobs x 2: Singapore (Clinical Research Network Director) and WHO (home-based consultant)
Dear All, Two fascinating job opportunities have appeared. Even if you’re not looking for a job, the job descriptions tell ...
Read More >
Mandatory reading: Alan Carr’s Jan 2020 Antibacterial and Antifungal market review
Dear All, Alan Carr has just released his Jan 2020 review of the antibacterial and antifungal market (link). For those ...
Read More >
News from Davos 2020: Some positive signs, but overall a fragile antibiotic market at a tipping point
Dear All (and heads-up for a rather lengthy and wonkish note … settle in for the details), Last week saw ...
Read More >